Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma

Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

“…The combination of paclitaxel and cisplatin with another novel agent, gemcitabine, has also been tested in several phase II trials. [23][24][25] The reported overall response rate is in the range of 50% to 70%, but at the expense of a similar toxic profile. Although the comparison of results from phase II trials certainly is not possible, the apparently lower response rates found when vinorelbine is used as the third agent might be in concordance with preclinical data showing antagonism when paclitaxel was administered before vinorelbine.…”

A comparison of toxicity profile of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer

“…Majority (68.7%) of patients in Arm B developed patchy hair loss and complete alopecia was seen in one patient belonging to same arm. Rodriguez et al 16 used combination of paclitaxel, cisplation and gemcitabine to treat metastatic NSCLC and the overall response rate was 71.4% with Grade 3-4 neutropenia and thrombocytopenia as the toxic effects of the combination observed among 39.9% and 11.4% of patients respectively. Ceribelli 18 The experimental arm showed to be not inferior to Arm A in terms of median and 1-year survival, with considerably less hematologic and non-hematologic toxicity.…”

Gemcitabine, Ifosfamide, and Cisplatin Combination (GIP) in Treatment of Patients With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer

“…15,27 These results are comparable to those observed for the triple drug combination of gemcitabine, paclitaxel, and cisplatin, for which the response rate is certainly higher (39 -57%) but the median survival is of the order of 15 months. 28,29 Since the initiation of this phase II GIP study, 4 other studies using the same combinations with different administration schedules have been reported, with a rate of response between 43% and 67% and a median survival between 12 and 15 months. 30 -33 Hence, all the triplet combinations based on a platinum agent appear to yield similar results, with median survival varying between 10 and 15 months, according to disease stage.…”